广泛期小细胞肺癌放化疗联合细胞免疫治疗的效果  

Efficacy of chemoradio-therapy combined with cell immune in the treatment of extensive small cell lung cancer

作　　者：赵华 艾月琴 郑劼 高艳荣 张闯 江龙委 胡建华 贾绍昌 

机构地区：[1]解放军第八一医院全军肿瘤中心肿瘤生物治疗科,江苏南京210002

出　　处：《中国医药导报》2016年第2期104-108,共5页China Medical Herald

摘　　要：目的探讨广泛期小细胞肺癌患者接受放化疗联合细胞免疫治疗后的疗效及影响预后的因素。方法回顾性分析解放军第八一医院生物治疗科2011年8月-2015年1月期间收治的21例广泛期小细胞肺癌患者的临床资料，综合治疗模式包括化疗＋放疗＋细胞治疗，采用Kaplan—Meier法进行单因素生存分析，Cox行多因素生存分析。结果全组患者中位生存期为20．7个月，1、2年生存率分别为85％、19％。单因素分析显示治疗方法（P=0．000）及治疗次数（P=0．001）显著影响患者的生存时间，多因素分析示治疗次数（P=0．087）和治疗方法（P=0．053）是影响患者预后的独立危险因素，而吸烟、年龄、肿瘤位置、神经元特异性烯醇化酶及乳酸脱氢酶等对患者预后无明显影响。结论广泛期小细胞肺癌的最优治疗方式仍有待进一步研究，但多学科综合治疗有望进一步提高患者的预后。Objective To evaluate the clinical efficacy of chemoradio-therapy combined with cell immune in the treatment of extensive small cell lung cancer （SCLC）. Methods The clinical data of 21 patients with extensive stage SCLC in No.81 Hospital of PEA from August 2011 to January 2015 were retrospectively analyzed. The comprehensive treatment approach included chemotherapy, radiotherapy and cell immunotherapy. The Kaplan-Meier and Cox estimation were used for the survival rate analysis. Results The median survival time of patients was 20.7 months, 1-year and 2- year survival rate was 85% and 19% respectively. Single-factor analysis showed that treatment methods （P=-0.000） and numbers （P=0.001） significantly affect the survival time of extensive stage SCLC patients. Moreover, multivariate analysis indicated that treatment numbers （P=0.087） and methods （P=0.053） were independtly associated with the risk of cancer-related death in extensive stage SCLC patients. Whereas smoking, age, tumor location, neuron-specific enolase and lactate dehydrogenase had no significant effects on prognosis. Conclusion The ideal treatment for extensive stage SCLC remains to be further studied, however, multidisciplinary-treatment is expected to further improve the prognosis for these patients.

关 键 词：小细胞肺癌 综合治疗 细胞治疗 预后 生存率 

分 类 号：R730.58[医药卫生—肿瘤]